COVID-19 information
Last updated February 2023
COVID-19 Vaccines
COVID-19 vaccines are now widely available to the Australian population. You can learn more about timelines and eligibility on the Department of Health website.
LINK: Department of Health website.
February 2023 – updated booster advice
What has changed:
- ATAGI recommends a 2023 COVID-19 vaccine booster dose for adults in the following groups, if their last COVID-19 vaccine dose or confirmed infection (whichever is the most recent) was 6 months ago or longer, and regardless of the number of prior doses received:
- All adults aged 65 years and over
- Adults aged 18-64 years who have medical comorbidities that increase their risk of severe COVID-19, or disability with significant or complex health needs.
- ATAGI advises the following groups should consider a 2023 booster dose if their last COVID-19 vaccine dose or confirmed infection (whichever is the most recent) was 6 months ago or longer, and regardless of the number of prior doses received, based on an individual risk benefit assessment with their immunisation provider.
- All Adults aged 18-64 years without risk factors for severe COVID-19
- Children and adolescents aged 5-17 years who have medical comorbidities that increase their risk of severe COVID-19, or disability with significant or complex health needs.
- ATAGI advises that a booster dose is not recommended at this time for children and adolescents aged under the age of 18 who do not have any risk factors for severe COVID-19.
- Regarding vaccine choice, all currently available COVID-19 vaccines are anticipated to provide benefit as a booster dose, however bivalent mRNA booster vaccines are preferred over other vaccines. These include: Pfizer Original/Omicron BA.4/5, as well as Pfizer Original/Omicron BA.1 or Moderna Original/Omicron BA.1. Moderna Original/Omicron BA.4/5 is currently under evaluation by the Therapeutic Goods Administration.
- COVID-19 vaccine can be co-administered with influenza and other vaccines.
- Administration of a 2023 COVID-19 booster dose should aim to occur prior to June 2023 and at a time of 6 months or greater following the most recent COVID-19 vaccine dose or confirmed infection.
- Ongoing surveillance of COVID-19 infection rates and clinical outcomes, new variants, and vaccine effectiveness will inform future recommendations for additional booster doses.
LINK: ATAGI advice – February 2023
July 2022 – winter COVID-19 vaccination eligbility
What has changed: a Winter booster dose is now available to:
- all adults aged 50 years and above (recommended)
- adults aged 30 and above have the option to receive a winter dose of a COVID-19 vaccine.
You can receive the winter dose 3 months after your previous dose or after being infected with COVID-19 if the infection has occurred since your previous dose.
LINK: ATAGI advice – July 2022
May 2022 – expanded winter dose recommendation
What has changed:
In this updated advice, an additional winter booster is now also recommended for other people at increased risk, to be given 4 months after their first booster dose. This applies to people aged 16-64 who have:
- A medical condition that increases the risk of severe COVID-19 illness – including chronic inflammatory conditions such as Crohn’s disease and ulcerative colitis. The full table of conditions is available at the link below.
- People with disability with significant or complex health needs or multiple comorbidities which increase risk of poor outcome from COVID-19.
LINK: ATAGI expanded recommendation – May 2022
March 2022 – winter dose recommendation
What has changed:
People aged 16 years and older who received a 3-dose primary course due to severe immunocompromise and a booster (4th) dose are now recommended to receive an additional winter booster dose of COVID-19 vaccine, from 4 months after their first booster.
LINK: ATAGI recommendation – March 2022
October 2021 – third dose recommendation
The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended a third dose of COVID-19 vaccine in individuals who are severely immunocompromised. More details are provided on the Department of Health website and indicate that limited IBD treatments are eligible. International evidence continues to build and CCA anticipates further advice from GESA and ATAGI in the future. If you have any queries, we encourage you to have a discussion with your clinical team. Changes to your medications should always be discussed with your doctor.
LINK: ATAGI recommendations on third dose
LINK: Third/booster dose update from GESA
Updates from ATAGI
The Australian Government Department of Health (DoH) and the Australian Technical Advisory Group on Immunisation (ATAGI) regularly provide updates regarding the vaccine safety and efficacy.
LINK: Australian Government Department of Health – News (ATAGI Updates)
Vaccine eligbility
The Department of Health has made a vaccine eligibility checker available.
LINK: Vaccine Eligibility Checker – HealthDirect
Information on Phase 1B eligibility for vaccination was made available directly from the Department of Health on 17 March 2021 and is shown below. It is recommended that you check with your healthcare professional for the best advice relating to your condition.
Phase 1B: Underlying Medical Conditions
Chronic inflammatory conditions on medical treatments
Including: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Crohn’s disease, ulcerative colitis, and similar who are being treated with Disease modifying anti-rheumatic drugs (DMARDs) or immune-suppressive or immunomodulatory therapies. Generally not inclusive of people living with osteoarthritis, fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome or similar non-immunocompromising inflammatory conditions.
Proof of eligibility – underlying medical conditions
- For individuals attending their usual GP, the clinic’s records may be relied upon as evidence
- MyHealth Record
- A referral from GP or treating specialist
- Alternative medical records, including:
- a printout of your medical history as recorded in your clinical records;
- a printout of your chronic disease care plan; a discharge summary from a hospital or other medical facility; or
- a valid script or medication prescribed to treat one or more of the relevant medical conditions
- Where none of these are available, individuals may complete a Phase 1B Declaration Form
Updates from GESA
The Gastroenterological Society of Australia (GESA) has released information on COVID-19 vaccination for people with gastrointestinal conditions (including Crohn’s and colitis) or liver diseases on immunosuppressive therapy which comments on safety and effectiveness.
LINK: Updated COVID Vaccination Information for Patients – GESA
CCA will continue to communicate up-to-date information regarding vaccines, particularly any impacts relating to people living with IBD.
About COVID-19
The respiratory illness COVID-19 (known generally as Coronavirus) is a virus that is the subject of a health alert in Australia, and has been declared a pandemic by the World Health Organisation.
Symptoms of COVID-19 can range from mild illness to pneumonia. Some people will recover easily, and others may get very sick very quickly. People with coronavirus may experience:
- fever
- flu-like symptoms such as coughing, sore throat and fatigue
- shortness of breath
Stay up to date
The Australian Government Department of Health provide a daily update on medical advice about COVID-19.
LINK: Daily Coronavirus Update – Australian Government Department of Health
Specific information on the current situation in each state/territory is available from government websites below:
Government support – Telehealth
Initial Primary Care announcement
(March 2020)
The Federal Government has announced a range of initiatives to support Australians during the COVID-19 pandemic including funding to allow doctors, nurses and mental health professionals to deliver services via telehealth to people with chronic diseases or who are immunocompromised.
LINK: Fact Sheet: Primary Care – Bulk Billed MBS Telehealth Services -March 2020
Telehealth update
(July 2020)
In a major boost for primary health care, the Australian Government is further strengthening telehealth arrangements as recommended by the Australian Medical Association (AMA) and the Royal Australian College of General Practitioners (RACGP) and other medical experts.
LINK: Media release – Continuous care with telehealth stage seven – July 2020
Permanent telehealth services from January 2022
(December 2021)
The Australian Government is investing $106 million over 4 years to support permanent telehealth services. This will allow GPs, specialists, and allied health professionals to continue consulting with their patients by phone or online.
LINK: Permanent telehealth for all Australians – December 2021
What does COVID-19 mean for people living with IBD?
Advice from GESA
The Gastroenterological Society of Australia (GESA) has provided information for people with gastrointestinal disorders. Click here to read the recommendations from GESA (published March 2020).
Immunosuppressed people
While immunosuppressed people are not at a greater risk of acquiring COVID-19 than the general population, it may have an impact on their ability to recover should they contract the virus.
Those who are on immunosuppressive medication [azathioprine, mercaptopurine, methotrexate, prednisolone, infliximab (Remicade, Inflectra), adalimumab (Humira), ustekinumab (Stelara), golimumab (Simponi), vedolizumab (Entyvio)] should make sure they follow all the measures to prevent person-to-person spread with:
- Social distancing (1.5m)
- Handwashing with soap and water, or alcohol based gels
- Avoidance of crowded areas
- Good basic hygiene- avoid touching your face and nose
If this is you, please also think about whether you can take additional measures to reduce contact with others, such as working from home where you can, or self-isolate in organisations that have large groups of people.
It is important to protect yourself against other common respiratory infections. Therefore, it is recommended that all patients with reduced immunity have the Influenza Vaccine (flu-shot) as soon as it is available.
IBD medications
There are no shortages of medication to treat IBD as a result of COVID-19 related demand at the moment. Some community pharmacies and hospitals are experiencing delays of a few days for delivery of some medications.
The government has restricted pharmacists to dispensing a one month supply for some medications, as a precautionary measure. This includes some pain relief and gastroenterological medications. For more information go to: https://www.tga.gov.au/media-release/covid-19-limits-dispensing-and-sales-pharmacies
People with IBD should be eligible for free delivery of medications once per month. For more information speak to your local pharmacy or visit: https://www.health.gov.au/resources/publications/covid-19-national-health-plan-home-medicines-services-information-for-consumers
IBD medicine restriction criteria lifted
PBS restriction criteria for some IBD medicines have been lifted to avoid medical appointments during COVID-19 pandemic. Prescribers can apply for an exemption for some medicines if a patient has had them prescribed before. Some biologic medicines used to treat IBD are included. For a full list of medicines and further details, visit: http://www.pbs.gov.au/info/news/2020/05/pharmaceutical-benefits-scheme-restriction-requirement
Children
GESA has provided advice on safe return to school for children with IBD. The detailed reasoning and some useful FAQs are provided here.
GESA has also previously provided advice to gastroenterologists on IBD management in children and young people:
- Recognition that age is a major risk factor for COVID-19 outcomes, but to be cautious about this as new information is collected
- Postponement of all non-urgent endoscopy procedures and guidance on safe endoscopy practices for urgent cases
- Using temporary MBS funded telehealth consultations where appropriate
- The need for patients to continue treatment unless a change is agreed with their IBD team
Mental health support
Beyond Blue have set up a resource page to help people manage their mental health during the COVID-19 pandemic. View their advice here.
The Australian Psychological Society has also provided tips on coping with COVID-19 related anxiety. Read those tips here.
Smoking cessation
Smoking can worsen IBD and according to the WHO it can increase your risk of COVID-19 infection and serious lung conditions such as pneumonia, see why here.
If you need support to stop smoking, visit QUIT.
COVID-19 worldwide data
A consortium of international IBD research organisations established a worldwide database to rapidly define the impact of COVID-19 on patients with IBD and how factors such as age, comorbidities, and IBD treatments impact COVID-19 outcomes. GPs and gastroenterologists added case reports to the database as soon as the diagnosis is made.
As at 25 January 2022, only 47 COVID-19 cases had been reported in Australia among those living with a diagnosed IBD since the beginning of the pandemic. There had been 7,038 cases reported worldwide. The database is now closed and information is available at: https://covidibd.org/
CCA support groups
Some of our support groups are still running, depending on location, while many are also meeting online. For the latest information please click here or call 1800 138 029.
Toilet access
As a result of COVID-19 restrictions, some council areas around Austraila may close various public toilet locations. Before commencing any necessary travel, we recommend contacting the local council in that area to check on open locations.
The National Public Toilet Map can be found here.
Toilet paper supply
CCA understand that some of our members are experiencing difficulties in purchasing toilet paper. This can be a stressful predicament for someone living with IBD.
In March 2020, we were pleased to see Woolworths take action to support people living with Crohn’s and Colitis who are taking immunosuppressive medication or are required to self isolate. For more information, visit this link.
A huge thank you to the team at Quilton who have generously donated 6,000 rolls of toilet paper to CCA to distribute to members who are most in need, as part of the Quilton 1 Million Rolls donation initiative.
Proudly supported by Roche Australia
Find support
For guidance regarding your IBD, Crohn’s & Colitis Australia continues to operate its support services:
- Crohn’s & Colitis Helpline: for individual help, information and guidance on Crohn’s disease or ulcerative colitis.
Call 1800 138 029 (option 1). - Crohn’s & Colitis NurseLine: To book an appointment to speak with a Registered Nurse with specialised knowledge of Crohn’s disease and ulcerative colitis (an IBD Nurse) who can help you with education, support and help you build your own personalised care plan.
Call 1800 138 029 (option 2)
